Thomas Weichhart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4478075/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacological inhibition of the mTOR pathway alters phenotype and cytokine expression in bovine monocyte-derived dendritic cells. Veterinary Immunology and Immunopathology, 2022, , 110441.	1.2	1
2	High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Respiratory Medicine, 2021, 177, 106294.	2.9	10
3	24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. Journal of Hepatology, 2021, 75, 1164-1176.	3.7	20
4	A fungal antigenic driver for Löfgren's syndrome sarcoidosis. Journal of Experimental Medicine, 2021, 218, .	8.5	5
5	mTORâ€dependent immunometabolism as Achilles' heel of anticancer therapy. European Journal of Immunology, 2021, , .	2.9	7
6	Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease. Cells, 2021, 10, 3545.	4.1	2
7	p38 regulates the tumor suppressor PDCD4 via the TSC-mTORC1 pathway. Cell Stress, 2021, 5, 176-182.	3.2	4
8	The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages. Nature Metabolism, 2020, 2, 1427-1442.	11.9	24
9	Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts. Journal of Clinical Medicine, 2020, 9, 2633.	2.4	43
10	Metabolic and immunologic control of intestinal cell function by mTOR. International Immunology, 2020, 32, 455-465.	4.0	10
11	Sarcoidosis and the mTOR, Rac1, and Autophagy Triad. Trends in Immunology, 2020, 41, 286-299.	6.8	59
12	Environmental arginine controls multinuclear giant cell metabolism and formation. Nature Communications, 2020, 11, 431.	12.8	37
13	Inverse Data-Driven Modeling and Multiomics Analysis Reveals Phgdh as a Metabolic Checkpoint of Macrophage Polarization and Proliferation. Cell Reports, 2020, 30, 1542-1552.e7.	6.4	52
14	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nature Communications, 2019, 10, 4741.	12.8	33
15	Metabolic Programming of Macrophages: Implications in the Pathogenesis of Granulomatous Disease. Frontiers in Immunology, 2019, 10, 2265.	4.8	53
16	Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. European Respiratory Journal, 2019, 54, 1900430.	6.7	43
17	Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight, 2019, 4, .	5.0	19
18	Whole exome sequencing in three families segregating a pediatric case of sarcoidosis. BMC Medical Genomics, 2018, 11, 23.	1.5	26

#	Article	IF	CITATIONS
19	mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review. Gerontology, 2018, 64, 127-134.	2.8	326
20	Iron Regulation: Macrophages in Control. Pharmaceuticals, 2018, 11, 137.	3.8	124
21	mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. Cell Reports, 2018, 23, 2157-2167.	6.4	62
22	TORching a semaphore for alternative macrophage activation. Nature Immunology, 2018, 19, 512-514.	14.5	4
23	New advances in the development of sarcoidosis models: a synopsis of a symposium sponsored by the Foundation for Sarcoidosis Research. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 2-4.	0.2	6
24	Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nature Immunology, 2017, 18, 293-302.	14.5	191
25	A New Immunomodulatory Role for Peroxisomes in Macrophages Activated by the TLR4 Ligand Lipopolysaccharide. Journal of Immunology, 2017, 198, 2414-2425.	0.8	45
26	Pro- versus Anti-inflammatory Actions of HDLs in Innate Immunity. Cell Metabolism, 2017, 26, 2-3.	16.2	6
27	<scp>mTORC</scp> 1 and <scp>mTORC</scp> 2 as regulators of cell metabolism in immunity. FEBS Letters, 2017, 591, 3089-3103.	2.8	194
28	04.05â€The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , .		0
29	HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2017, 28, 769-775.	6.1	45
30	Effects of Interferons and Viruses on Metabolism. Frontiers in Immunology, 2016, 7, 630.	4.8	96
31	mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function. Trends in Immunology, 2016, 37, 778-789.	6.8	93
32	Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers. BMC Immunology, 2016, 17, 11.	2.2	7
33	A2.6â€MTOR plays a decisive role in the mesenchymal tissue response to inflammation in arthritis. Annals of the Rheumatic Diseases, 2015, 74, A18.1-A18.	0.9	0
34	Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties. Journal of the American Society of Nephrology: JASN, 2015, 26, 565-575.	6.1	37
35	Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 224-231.	4.5	54
36	Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. Transplant Immunology, 2015, 33, 45-50.	1.2	11

#	Article	IF	CITATIONS
37	HDL Cholesterol Efflux Capacity and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1869-1872.	27.0	38
38	Regulation of innate immune cell function by mTOR. Nature Reviews Immunology, 2015, 15, 599-614.	22.7	612
39	Lysis Gradient Centrifugation: A Flexible Method for the Isolation of Nuclei from Primary Cells. Methods in Molecular Biology, 2015, 1228, 15-23.	0.9	5
40	HDL-Proteine sind mit kardiovaskuläem Risiko und Mortalitäbei Patienten mit Typ 2-Diabetes an der Hänodialyse assoziiert. Nieren- Und Hochdruckkrankheiten, 2015, 44, 159-165.	0.0	0
41	mTORC1 Is Essential for Early Steps during Schwann Cell Differentiation of Amniotic Fluid Stem Cells and Regulates Lipogenic Gene Expression. PLoS ONE, 2014, 9, e107004.	2.5	15
42	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opinion on Drug Safety, 2014, 13, 361-372.	2.4	30
43	Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 944-953.	2.4	19
44	Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 72-79.	3.0	19
45	p38α Senses Environmental Stress To Control Innate Immune Responses via Mechanistic Target of Rapamycin. Journal of Immunology, 2013, 190, 1519-1527.	0.8	27
46	Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochemical Society Transactions, 2013, 41, 927-933.	3.4	72
47	Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 902-905.	0.7	83
48	Serum Amyloid A in Uremic HDL Promotes Inflammation. Journal of the American Society of Nephrology: JASN, 2012, 23, 934-947.	6.1	194
49	PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113
50	Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. Trials, 2012, 13, 79.	1.6	15
51	Mammalian Target of Rapamycin: A Signaling Kinase for Every Aspect of Cellular Life. Methods in Molecular Biology, 2012, 821, 1-14.	0.9	107
52	CMV Late Phase-Induced mTOR Activation Is Essential for Efficient Virus Replication in Polarized Human Macrophages. American Journal of Transplantation, 2012, 12, 1458-1468.	4.7	64
53	Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood, 2011, 117, 4273-4283.	1.4	121
54	Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone. Transplantation Reviews, 2011, 25, 145-153.	2.9	8

#	Article	IF	CITATIONS
55	Rapid isolation of nuclei from living immune cells by a single centrifugation through a multifunctional lysis gradient. Journal of Immunological Methods, 2011, 373, 167-173.	1.4	13
56	Effect of the Proteasome Inhibitor Bortezomib on Humoral Immunity in Two Presensitized Renal Transplant Candidates. Transplantation, 2010, 89, 1385-1390.	1.0	60
57	Sirolimus and Kidney Transplantation: Unraveling an Inflammatory Affair. American Journal of Transplantation, 2010, 10, 2569-2570.	4.7	3
58	The anti-inflammatory potency of dexamethasone is determined by the route of application in vivo. Immunology Letters, 2010, 129, 50-52.	2.5	14
59	T Helper Cell Differentiation: Understanding the Needs of Hierarchy. Immunity, 2010, 32, 727-729.	14.3	7
60	A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials, 2010, 11, 91.	1.6	16
61	The versatility of HDL: a crucial antiâ€inflammatory regulator. European Journal of Clinical Investigation, 2010, 40, 1131-1143.	3.4	77
62	Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. Transplant International, 2010, 23, 777-785.	1.6	20
63	Neutralization of Osteopontin Inhibits Obesity-Induced Inflammation and Insulin Resistance. Diabetes, 2010, 59, 935-946.	0.6	170
64	A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation. Journal of Immunology, 2010, 185, 3919-3931.	0.8	205
65	The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity. American Journal of Transplantation, 2009, 9, 2655-2661.	4.7	187
66	Late onset <i>Pneumocystis</i> pneumonia in renal transplantation after longâ€ŧerm immunosuppression with belatacept. Transplant Infectious Disease, 2009, 11, 171-174.	1.7	25
67	The multiple facets of mTOR in immunity. Trends in Immunology, 2009, 30, 218-226.	6.8	241
68	Current concepts of molecular defence mechanisms operative during urinary tract infection. European Journal of Clinical Investigation, 2008, 38, 29-38.	3.4	115
69	Biological Action of Rapamycin in Renal Transplantation. American Journal of Kidney Diseases, 2008, 51, 531.	1.9	3
70	The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response. Immunity, 2008, 29, 565-577.	14.3	687
71	The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Annals of the Rheumatic Diseases, 2008, 67, iii70-iii74.	0.9	240
72	Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. Journal of Leukocyte Biology, 2008, 83, 131-138.	3.3	33

#	Article	IF	CITATIONS
73	Osteopontin Expression in Human and Murine Obesity: Extensive Local Up-Regulation in Adipose Tissue but Minimal Systemic Alterations. Endocrinology, 2008, 149, 1350-1357.	2.8	136
74	Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-κB in immunological synapse formation. Journal of Leukocyte Biology, 2007, 81, 319-327.	3.3	20
75	Antithymocyte Globulin Impairs T-Cell/Antigen-Presenting Cell Interaction: Disruption of Immunological Synapse and Conjugate Formation. Transplantation, 2007, 84, 117-121.	1.0	28
76	Toll-like receptors and chondrocytes: The lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis and Rheumatism, 2007, 56, 1880-1893.	6.7	108
77	Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. International Journal of Obesity, 2007, 31, 1004-1013.	3.4	121
78	Uncovering host defences in the urinary tract: cathelicidin and beyond. Nephrology Dialysis Transplantation, 2006, 22, 347-349.	0.7	7
79	Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. European Journal of Clinical Investigation, 2005, 35, 227-235.	3.4	75
80	The multiple functions of Tamm–Horsfall protein in human health and disease: A mystery clears up. Wiener Klinische Wochenschrift, 2005, 117, 316-322.	1.9	25
81	Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4–dependent mechanism. Journal of Clinical Investigation, 2005, 115, 468-475.	8.2	193
82	Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4–dependent mechanism. Journal of Clinical Investigation, 2005, 115, 468-475.	8.2	131
83	Functional Selection of Vaccine Candidate Peptides from Staphylococcus aureus Whole-Genome Expression Libraries In Vitro. Infection and Immunity, 2003, 71, 4633-4641.	2.2	62
84	PTX3 Inhibits Complement-Driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	5